Atrium Health Levine Cancer Institute | Strategic Alliance Partners

Latest from Atrium Health Levine Cancer Institute

Crane Helps Gynecologic Fellows Deliver Care in a Complicated Time

November 21, 2022

Dr Crane discusses why Atrium Health decided to launch a gyn onc fellowship, how she helps fellows navigate the current political landscape while maintaining high-level care, and how she tries to model a good work-life balance for her trainees.

CAR T-Cell Therapies Improve Treatment Landscape in Relapsed/Refractory Multiple Myeloma

November 08, 2022

The increasing integration of CAR T-cell therapies into the treatment paradigm for adult patients with relapsed or refractory multiple myeloma addresses several unmet needs and improves outcomes for this historically limited patient population.

Atrium Health Levine Cancer Institute’s Breast Program Earns NAPBC Accreditation

November 07, 2022

Atrium Health Levine Cancer Institute’s breast cancer program has been granted accredited status by the National Accreditation Program for Breast Centers, a quality program administered by the American College of Surgeons.

Treatments Branch Out in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

October 18, 2022

Peter Voorhees, MD, highlights important topics that his colleagues discussed at the meeting, including the important role of up-front autologous stem cell transplant and distinct adverse effects to be aware of when using different CAR T-cell therapies.

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28, 2022

Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.

Seribantumab Demonstrates Positive Response Rates, Tolerability in NRG1 Fusion+ Solid Tumors

July 14, 2022

Daniel R. Carrizosa, MD, MS, discusses the design and important efficacy and safety findings from CRESTONE trial evaluating seribantumab and the importance of finding a targeted therapy for patients with solid tumors harboring NRG1 fusions.

Lung Cancer Management Methods Expand to Encompass Multiple Treatment Perspectives

April 14, 2022

New treatment methods in patients with small cell lung cancer and non–small cell lung cancer are on the horizon, with the introduction of combination immunotherapy, biomarker assays, and supportive oncology programs for patients and care partners.